452 related articles for article (PubMed ID: 16837130)
1. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
[TBL] [Abstract][Full Text] [Related]
2. Selective downregulation of EGF receptor and downstream MAPK pathway in human cancer cell lines by active components partially purified from the seeds of Livistona chinensis R. Brown.
Huang WC; Hsu RM; Chi LM; Leu YL; Chang YS; Yu JS
Cancer Lett; 2007 Apr; 248(1):137-46. PubMed ID: 16919867
[TBL] [Abstract][Full Text] [Related]
3. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
[TBL] [Abstract][Full Text] [Related]
4. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
Johnson FM; Saigal B; Donato NJ
J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
[TBL] [Abstract][Full Text] [Related]
5. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
6. Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells.
Kim SH; Song YC; Kim SH; Jo H; Song YS
Ann N Y Acad Sci; 2009 Aug; 1171():642-8. PubMed ID: 19723115
[TBL] [Abstract][Full Text] [Related]
7. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
Höpfner M; Sutter AP; Huether A; Schuppan D; Zeitz M; Scherübl H
J Hepatol; 2004 Dec; 41(6):1008-16. PubMed ID: 15582135
[TBL] [Abstract][Full Text] [Related]
8. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells.
Lee LT; Huang YT; Hwang JJ; Lee PP; Ke FC; Nair MP; Kanadaswam C; Lee MT
Anticancer Res; 2002; 22(3):1615-27. PubMed ID: 12168845
[TBL] [Abstract][Full Text] [Related]
9. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.
Moyer JD; Barbacci EG; Iwata KK; Arnold L; Boman B; Cunningham A; DiOrio C; Doty J; Morin MJ; Moyer MP; Neveu M; Pollack VA; Pustilnik LR; Reynolds MM; Sloan D; Theleman A; Miller P
Cancer Res; 1997 Nov; 57(21):4838-48. PubMed ID: 9354447
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
Rewcastle GW; Palmer BD; Bridges AJ; Showalter HD; Sun L; Nelson J; McMichael A; Kraker AJ; Fry DW; Denny WA
J Med Chem; 1996 Feb; 39(4):918-28. PubMed ID: 8632415
[TBL] [Abstract][Full Text] [Related]
11. Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression.
Ahmad N; Gali H; Javed S; Agarwal R
Biochem Biophys Res Commun; 1998 Jun; 247(2):294-301. PubMed ID: 9642119
[TBL] [Abstract][Full Text] [Related]
12. Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor.
Harper ME; Goddard L; Glynne-Jones E; Assender J; Dutkowski CM; Barrow D; Dewhurst OL; Wakeling AE; Nicholson RI
Prostate; 2002 Jun; 52(1):59-68. PubMed ID: 11992620
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase.
Cohen EE; Lingen MW; Zhu B; Zhu H; Straza MW; Pierce C; Martin LE; Rosner MR
Cancer Res; 2006 Jun; 66(12):6296-303. PubMed ID: 16778206
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer.
Kalli KR; Bradley SV; Fuchshuber S; Conover CA
Gynecol Oncol; 2004 Sep; 94(3):705-12. PubMed ID: 15350362
[TBL] [Abstract][Full Text] [Related]
15. Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41.
Matheson SL; McNamee JP; Jean-Claude BJ
Cancer Chemother Pharmacol; 2003 Jan; 51(1):11-20. PubMed ID: 12497201
[TBL] [Abstract][Full Text] [Related]
16. Control of cell motility by interaction of gangliosides, tetraspanins, and epidermal growth factor receptor in A431 versus KB epidermoid tumor cells.
Park SY; Yoon SJ; Freire-de-Lima L; Kim JH; Hakomori SI
Carbohydr Res; 2009 Aug; 344(12):1479-86. PubMed ID: 19559406
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of normal, paramalignant, and malignant human urothelial cells to inhibitors of the epidermal growth factor receptor signaling pathway.
MacLaine NJ; Wood MD; Holder JC; Rees RW; Southgate J
Mol Cancer Res; 2008 Jan; 6(1):53-63. PubMed ID: 18234962
[TBL] [Abstract][Full Text] [Related]
18. Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4.
Kaufmann R; Rahn S; Pollrich K; Hertel J; Dittmar Y; Hommann M; Henklein P; Biskup C; Westermann M; Hollenberg MD; Settmacher U
J Cell Physiol; 2007 Jun; 211(3):699-707. PubMed ID: 17323377
[TBL] [Abstract][Full Text] [Related]
19. Tyrphostin AG1478 suppresses proliferation and invasion of human breast cancer cells.
Zhang YG; Du Q; Fang WG; Jin ML; Tian XX
Int J Oncol; 2008 Sep; 33(3):595-602. PubMed ID: 18695891
[TBL] [Abstract][Full Text] [Related]
20. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.
Younes MN; Yazici YD; Kim S; Jasser SA; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3425-34. PubMed ID: 16740767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
